Buy (150 RUB)
Generate QR code
Open Access
Subscription or Fee Access
Neuroendocrine prostate cancer (clinical case)
https://doi.org/10.33667/2078-5631-2024-27-55-59
Abstract
Neuroendocrine prostate cancer is a rare and aggressive cancer with a poor prognosis. This type of cancer is often diagnosed at an advanced stage and exhibits rapid resistance to standard therapeutic methods. Taking into account the low occurrence of this phenomenon, a description of poorly differentiated neuroendocrine (small cell) prostate cancer with extremely aggressive forms is given.
About the Authors
G A. Khakimov
Tashkent Pediatric Medical Institute; Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology
Uzbekistan
Uzbekistan
Khakimov Golib A., DM Sci (habil.), prof., head of Dept of Pediatric Oncology, Palliative Care; director
Tashkent
G. G. Khakimova
Tashkent Pediatric Medical Institute; Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology; 4 Moscow Institute of Clinical Medicine N.V. Sklifosovsky, I.M. Sechenov First Moscow State Medical University (Sechenov University)
Uzbekistan
Uzbekistan
Khakimova Gulnoz G., PhD Med, associate prof. at Dept of Pediatric Oncology, Palliative Care; oncologist; intern of Dept of Oncology, Radiotherapy and Reconstructive Surgery
Tashkent; Moscow
S. F. Dallo
Tashkent Pediatric Medical Institute
Uzbekistan
Uzbekistan
Dallo Salva F., assistant at Dept of Oncology, Oncohematology, Radiation Oncology
Tashkent
Sh. G. Khakimova
Tashkent Pediatric Medical Institute; Moscow Research Oncology Institute P.A. Herzen – branch of the National Medical Research Center of Radiology
Uzbekistan
Uzbekistan
Khakimova Shakhnoz G., DM Sci (habil.), associate prof. at Dept of Pediatric Oncology, palliative care; oncologist
Tashkent; Moscow
A. M. Khakimov
Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology
Uzbekistan
Uzbekistan
Khakimov Abdugiyaz M., oncologist
Tashkent
References
1. Aggarwal R., Zhang T., Small E.J., Armstrong A. J. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J. Natl. Compr. Canc. Netw. 2014; 12 (5): 719–26. DOI: 10.6004/jnccn.2014.0073
2. Hirano D., Okada Y., Minei S. et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur. Urol. 2004; 45 (5): 586–92. DOI: 10.1016/j.eururo.2003.11.032
3. Aggarwal R., Huang J., Alumkal J.J. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 2018; 36 (24): 2492–503. DOI: 10.1200/JCO.2017.77.6880
4. Abida W., Cyrta J., Heller G. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl. Acad. Sci. USA. 2019; 116 (23): 11428–36. DOI: 10.1073/pnas.1902651116
5. Bluemn E.G., Coleman I.M., Lucas J.M. et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF sig- naling. Cancer Cell. 2017; 32 (4): 474–89. DOI: 10.1016/j.ccell.2017.09.003
6. Beltran H., Prandi D., Mosquera J.M. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 2016; 22 (3): 298–305. DOI: 10.1038/nm.4045
7. Zhang Y., Zheng D., Zhou T. et al. Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB- EZH2-TSP1 pathway in prostate cancers. Nat. Commun. 2018; 9 (1): 4080. DOI: 10.1038/s41467-018-06177-2
8. Puca L., Vlachostergios P. J., Beltran H. Neuroendocrine differentiation in prostate cancer: emerging biology, models, and therapies. Cold Spring Harb Perspect Med. 2019; 9 (2): 30593. DOI: 10.1101/cshperspect.a030593
9. Montironi R., Cimadamore A., Lopez-Beltran A. et al. Morphologic, molecular and clinical features of aggressive variant prostate cancer. Cells. 2020; 9 (5): 1073. DOI: 10.3390/cells9051073
10. Mahal B.A., Yang D.D., Wang N.Q. et al. Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate can- cer. Eur. Urol. 2018; 74 (2): 146–54. DOI: 10.1016/j.eururo.2018.01.043
11. Wang J., Xu W., Mierxiati A. et al. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer. Prostate. 2019; 79 (13): 1563–71. DOI: 10.1002/pros.23878
12. Helpap B., Köllermann J., Oehler U. Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives. Urol. Int. 1999; 62 (3): 133–8.
13. Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, et al. Prognostic value of serum markers for prostate cancer. Scand. J. Urol. Nephrol. Suppl. 2005; (216): 64–81.
14. Nadal R., Schweizer M., Kryvenko O.N., Epstein J.I., Eisenberger M.A. Small cell carcinoma of the prostate. Nat. Rev. Urol. 2014; 11 (4): 213–9.
15. Conteduca V., Oromendia C., Eng K.W., Bareja R., Sigouros M., Molina A. et al. Clinical features of neuroendocrine prostate cancer. Eur. J. Cancer. 2019; 121: 7–18.
16. Apostolidis L., Nientiedt C., Winkler E.C. et al. Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. Oncotarget. 2019; 10 (1): 17–29. DOI: 10.18632/oncotarget.26523
17. Zhu J., Liang X., Wu D. et al. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: a population-based study. Medicine (Baltimore). 2021; 100 (15): 25237. DOI: 10.1097/MD.0000000000025237
18. Vlachostergios P.J., Papandreou C.N. Targeting neuroendocrine prostate cancer: molecular and clinical perspectives. Front Oncol. 2015; 5: 6. DOI: 10.3389/fonc.2015.00006
19. Papandreou C. N., Daliani D. D., Thall P. F. et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J. Clin. Oncol. 2002; 20 (14): 3072–80. DOI: 10.1200/JCO.2002.12.065
20. Culine S., El Demery M., Lamy P.J. et al. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J. Urol. 2007; 178: 844–8. DOI: 10.1016/j.juro.2007.05.044
21. Schaeffer E.M., Srinivas S., Adra N., An Y., Barocas D., Bitting R. et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2023; 21 (10): 1067–96.
22. Duran I., Berthold D.R., Pond G.R. et al. Meeting: 2007 Prostate Cancer Symposium. Abstract No. 253. Neuroendocrine carcinoma of the prostate: Review of 14 cases at a single institution from 1988–2004.
23. Stein M., Bernstein Z., Abacioglu U. et al. Small cell (neuroendocrine) carcinomas of the prostate: etiology, diagnosis, prognosis and therapeutic implications – a retrospective study of 30 patients from rare cancer network. Am.J. Med. Scienc. 2008; 336 (6): 478–88.
24. Safina S. Z., Isyangulova A. Z. Neuroendocrine prostate cancer. Cancer Urology. 2023;19(2):94–100. (In Russ.) DOI:10.17650/1726-9776-2023-19-2-94-100
25. Umar S.A., Maclenna G.T. Small cell carcinoma of the prostate. J. Urol. 2009; 181 (2): 838–9. DOI: 10.1038/nrurol.2014.21
26. Conteduca V., Oromendia C., Eng K.W. et al. Clinical features of neuroendocrine prostate cancer. Eur. J. Cancer. 2019; 121: 7–18. DOI: 10.1016/j.ejca.2019.08.011
Review
For citations:
Khakimov G.A., Khakimova G.G., Dallo S.F., Khakimova Sh.G., Khakimov A.M. Neuroendocrine prostate cancer (clinical case). Diagnostics and Oncotherapy (3). 2024;(27):55-59. (In Russ.) https://doi.org/10.33667/2078-5631-2024-27-55-59
Views:
379
Email this article 